low dose in newborn rats attenuates hyperoxia-induced lung and heart injury at a Angiotensin II type 2 receptor ligand PD123319
暂无分享,去创建一个
F. Walther | Xueyu Chen | G. Folkerts | G. Wagenaar | R. M. A. Sengers | A. Roks | Melissa P. H. A. Lindeboom
[1] R. Morty,et al. Recent advances in late lung development and the pathogenesis of bronchopulmonary dysplasia. , 2013, American journal of physiology. Lung cellular and molecular physiology.
[2] F. Walther,et al. Agonists of MAS oncogene and angiotensin II type 2 receptors attenuate cardiopulmonary disease in rats with neonatal hyperoxia-induced lung injury. , 2013, American journal of physiology. Lung cellular and molecular physiology.
[3] L. Leng,et al. A Critical Regulatory Role for Macrophage Migration Inhibitory Factor in Hyperoxia-Induced Injury in the Developing Murine Lung , 2013, PloS one.
[4] R. Charnigo,et al. PD123319 Augments Angiotensin II-Induced Abdominal Aortic Aneurysms through an AT2 Receptor-Independent Mechanism , 2013, PloS one.
[5] J. Jankowski,et al. Discovery and Characterization of Alamandine: A Novel Component of the Renin–Angiotensin System , 2013, Circulation research.
[6] A. Danser,et al. Angiotensin II type 2 receptor agonists: where should they be applied? , 2012, Expert opinion on investigational drugs.
[7] B. Uhal,et al. Angiotensin signalling in pulmonary fibrosis. , 2012, The international journal of biochemistry & cell biology.
[8] J. Penninger,et al. Angiotensin converting enzyme 2 abrogates bleomycin-induced lung injury , 2012, Journal of Molecular Medicine.
[9] C. Cheadle,et al. Angiotensin receptor blockade attenuates cigarette smoke-induced lung injury and rescues lung architecture in mice. , 2012, The Journal of clinical investigation.
[10] H. Chou,et al. Angiotensin II Type 1 Receptor Antagonist Attenuates Lung Fibrosis in Hyperoxia-Exposed Newborn Rats , 2012, Journal of Pharmacology and Experimental Therapeutics.
[11] R. Lutter,et al. Acute respiratory distress syndrome leads to reduced ratio of ACE/ACE2 activities and is prevented by angiotensin‐(1–7) or an angiotensin II receptor antagonist , 2011, The Journal of pathology.
[12] Zhenqi Liu,et al. Angiotensin II Receptors Modulate Muscle Microvascular and Metabolic Responses to Insulin In Vivo , 2011, Diabetes.
[13] J. Dyck,et al. Activation of Akt protects alveoli from neonatal oxygen-induced lung injury. , 2011, American journal of respiratory cell and molecular biology.
[14] F. Walther,et al. Apelin attenuates hyperoxic lung and heart injury in neonatal rats. , 2010, American journal of respiratory and critical care medicine.
[15] L. P. de Sousa,et al. Anti-Inflammatory Effects of the Activation of the Angiotensin-(1–7) Receptor, Mas, in Experimental Models of Arthritis , 2010, The Journal of Immunology.
[16] M. Raizada,et al. The angiotensin-converting enzyme 2/angiogenesis-(1-7)/Mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension. , 2010, American journal of respiratory and critical care medicine.
[17] T. Unger,et al. The angiotensin AT2 receptor in left ventricular hypertrophy , 2010, Journal of hypertension.
[18] R. Fraga-Silva,et al. Vascular Relaxation, Antihypertensive Effect, and Cardioprotection of a Novel Peptide Agonist of the Mas Receptor , 2010, Hypertension.
[19] T. Zuberbier,et al. Direct Angiotensin II Type 2 Receptor Stimulation Acts Anti-Inflammatory Through Epoxyeicosatrienoic Acid and Inhibition of Nuclear Factor &kgr;B , 2010, Hypertension.
[20] R. Steinhorn. Neonatal pulmonary hypertension , 2010, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.
[21] P. Thistlethwaite,et al. Development and pathology of pulmonary hypertension. , 2009, Journal of the American College of Cardiology.
[22] J. L. Hansen,et al. Functional interactions between 7TM receptors in the Renin-Angiotensin System—Dimerization or crosstalk? , 2009, Molecular and Cellular Endocrinology.
[23] W. Seeger,et al. Inhibition of phosphodiesterase 4 enhances lung alveolarisation in neonatal mice exposed to hyperoxia , 2009, European Respiratory Journal.
[24] S. Abman. Role of endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. , 2009, Annual review of medicine.
[25] B. Uhal,et al. Angiotensin converting enzyme-2 is protective but downregulated in human and experimental lung fibrosis. , 2008, American journal of physiology. Lung cellular and molecular physiology.
[26] M. Fujimura,et al. Angiotensin II type 2 receptor antagonist reduces bleomycin-induced pulmonary fibrosis in mice , 2008, Respiratory research.
[27] D. Newby,et al. The apelin-APJ system in heart failure: pathophysiologic relevance and therapeutic potential. , 2008, Biochemical pharmacology.
[28] F. Walther,et al. Phosphodiesterase-4 inhibition attenuates pulmonary inflammation in neonatal lung injury , 2008, European Respiratory Journal.
[29] E. Baraldi,et al. Chronic lung disease after premature birth. , 2007, The New England journal of medicine.
[30] C. Ferrario,et al. Angiotensin-(1-7): pharmacology and new perspectives in cardiovascular treatments. , 2007, Cardiovascular drug reviews.
[31] S. Abman. Recent Advances in the Pathogenesis and Treatment of Persistent Pulmonary Hypertension of the Newborn , 2007, Neonatology.
[32] J. Pesquero,et al. Functional expression of kinin B1 and B2 receptors in mouse abdominal aorta. , 2007, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.
[33] J. Mullol,et al. Losartan attenuates bleomycin induced lung fibrosis by increasing prostaglandin E2 synthesis , 2006, Thorax.
[34] Arthur S Slutsky,et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure , 2005, Nature.
[35] A. Tanswell,et al. Opposing effects of 60% oxygen and neutrophil influx on alveologenesis in the neonatal rat. , 2004, American journal of respiratory and critical care medicine.
[36] T. Shinohara,et al. Identification of a G Protein-coupled Receptor Specifically Responsive to β-Alanine* , 2004, Journal of Biological Chemistry.
[37] L. Juillerat-Jeanneret,et al. Angiotensin II Type 2 Receptor–Mediated Vasodilation in Human Coronary Microarteries , 2004, Circulation.
[38] F. Walther,et al. Gene expression profile and histopathology of experimental bronchopulmonary dysplasia induced by prolonged oxidative stress. , 2004, Free radical biology & medicine.
[39] Thomas Walther,et al. Angiotensin-(1–7) is an endogenous ligand for the G protein-coupled receptor Mas , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[40] K. Nakao,et al. Angiotensin II Type 2 Receptor Deficiency Exacerbates Heart Failure and Reduces Survival After Acute Myocardial Infarction in Mice , 2003, Circulation.
[41] A. Davenport,et al. [125I]‐(Pyr1)Apelin‐13 is a novel radioligand for localizing the APJ orphan receptor in human and rat tissues with evidence for a vasoconstrictor role in man , 2001, British journal of pharmacology.
[42] Shokei Kim,et al. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. , 2000, Pharmacological reviews.
[43] A. Jobe. The New BPD: An Arrest of Lung Development , 1999, Pediatric Research.
[44] A. Tanswell,et al. α1-Antitrypsin Protects Neonatal Rats from Pulmonary Vascular and Parenchymal Effects of Oxygen Toxicity , 1994, Pediatric Research.
[45] A. Nishio,et al. Characterization of muscarinic receptor subtype mediating contraction and relaxation in equine coronary artery in vitro. , 1994, Journal of veterinary pharmacology and therapeutics.
[46] R. Chambers,et al. Angiotensin II and the fibroproliferative response to acute lung injury. , 2004, American journal of physiology. Lung cellular and molecular physiology.